Trial · NCT07480863
Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL
NCT07480863, Phase 2, Active not recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL. Trials, record NCT07480863. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07480863
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL
- NCT number
- NCT07480863
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 65 participants, estimated
- Lead sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Conditions
- Marginal Zone Lymphoma(MZL)
- Interventions
- Orelabrutinib, Zuberitamab, Cyclophosphamide, Vincristine, Prednisoneacetatetablets
- First posted
- 2026-03-18
- Last updated
- 2026-04-02
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 24-month complete remission rate | From enrollment to 24 months | All visible tumor lesions have completely disappeared, no new lesions have appeared, and this has been maintained for at least 4 weeks at 24-month. |
| Secondary | Objective response rate (ORR) at the end of induction therapy | From enrollment to the end of induction treatment at 8 weeks | The overall response rate (ORR) was defined as the cumulative proportion of patients attaining either a complete response (CR) or partial response (PR) at the end of induction therapy . |
| Secondary | Complete remission rate (CRR) at the end of induction therapy | From enrollment to the end of induction treatment at 8 weeks | All visible tumor lesions have completely disappeared, no new lesions have appeared, and this has been maintained for at least 4 weeks at the end of induction therapy. |
| Secondary | 24-month progression-free survival rate | From enrollment to 24 months | PFS defined as the time from RD initiation to first documented disease progression, relapse after RD, death from any cause, or last follow-up at 24-month.. |
| Secondary | 24-Month Overall Survival Rate | From enrollment to 24 months | OS was measured from RD start to death or last follow-up at 24-month. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07480863
GET https://conductscience.org/api/trials/v1/NCT07480863/registered